FDA Accepts HeartBeam System Into TAP Pilot Program
HeartBeam said the FDA accepted its system into the agency’s Total Product Life Cycle Advisory Program pilot.
Story updates
12:31:46 PM UTC
SquawkNews
HeartBeam was accepted into FDA’s TAP Pilot for its 3D ECG heart attack assessment technology, following Breakthrough Device Designation. TAP provides proactive FDA guidance and payer engagement but does not guarantee authorization or coverage.Material DetailsContext by AI AnalystThis extends a rec…
12:34:03 PM UTC
SquawkNews
Acceptance into FDA’s TAP Pilot follows Breakthrough Device Designation granted earlier this month f